Valuation: Lexington BioSciences Inc

Market Cap 3.94K 2.78K 2.44K 2.24K 2.1K 262K 4.02K 26.98K 10.44K 129K 10.43K 10.2K 449K P/E 2022
-
P/E 2023 -
Enterprise Value 3.94K 2.78K 2.44K 2.24K 2.1K 262K 4.02K 26.98K 10.44K 129K 10.43K 10.2K 449K EV / Sales 2022
-
EV / Sales 2023 -
Free-Float
13.79%
Yield 2022 *
-
Yield 2023 -
24-11-28 Registered Plan Private Investments Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 CI
24-08-23 Registered Plan Private Investments Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 CI
24-05-24 Registered Plan Private Investments Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
24-04-30 Registered Plan Private Investments Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
24-04-29 Registered Plan Private Investments Inc. Auditor Raises 'Going Concern' Doubt CI
23-11-28 Registered Plan Private Investments Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
23-09-04 Registered Plan Private Investments Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
23-05-30 Registered Plan Private Investments Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
23-05-02 Registered Plan Private Investments Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
23-05-01 Registered Plan Private Investments Inc. Auditor Raises 'Going Concern' Doubt CI
22-11-29 Registered Plan Private Investments Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
22-08-30 Registered Plan Private Investments Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
22-05-29 Registered Plan Private Investments Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Manager TitleAgeSince
Chief Executive Officer 62 2020-04-15
Director of Finance/CFO 68 -
Director TitleAgeSince
Director/Board Member 68 2016-12-20
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
-23.23%-.--% - - 2.74K
+0.94%+6.46%-29.96%-12.68% 164B
+1.48%+2.07%-5.86%-7.08% 104B
-0.29%+5.26%-4.44%+51.57% 55.67B
-2.09%-6.13%+50.84%+54.81% 52.92B
+3.00%+8.29%-8.74%-39.62% 42.96B
+2.91%+8.15% - - 32.87B
+2.17%-3.22%-18.75%-43.21% 27.07B
+1.24%+6.98%+60.30%-5.01% 24.79B
+2.41%+6.45%-9.68%-0.53% 21.02B
Average -1.15%+3.42%+4.21%-0.22% 58.32B
Weighted average by Cap. +1.04%+3.85%-5.42%-0.10%

Financials

2022 2023
Net sales - -
Net income -176K -124K -109K -100K -93.84K -11.7M -180K -1.2M -466K -5.78M -466K -456K -20.05M -177K -125K -110K -101K -94.6K -11.79M -181K -1.21M -470K -5.83M -469K -459K -20.21M
Net Debt - -
Logo Lexington BioSciences Inc
Lexington Biosciences Holdings Corp., formerly Lexington Biosciences Inc., is a Canada-based medical device company, which core business is to develop and commercialize non-invasive diagnostic product HeartSentry to monitor cardiovascular health by assessing the function of a person’s vascular endothelium - the vital innermost lining of a person’s cardiovascular system. The device measures the function of the endothelium, the cells that line all arteries and are critical to the prevention of atherosclerosis, heart attacks and stroke. The company is in the final stages of releasing the developed product for clinical studies. The Company's goal is to make HeartSentry accurate, quick, and cost effective so it can become the standard of care for cardiologists, general practitioners, and ultimately patients for first line evaluation of a person’s cardiovascular health.
Employees
-